Table 3. Salvage chemotherapy novel... | American Society of Hematology

Table 3.

Salvage chemotherapy + novel agent salvage therapy in relapsed/refractory Hodgkin lymphoma

Regimen	Number of patients	ORR (%)	CR (%)	Reference
Sequential BV-chemo	37	68^a	35^a	24
BV- ESHAP	66	91^a	70^a	25
BV-ICE	16	94^a	69^a	26
BV-DHAP	12	100^a	100^a	27
BV-bendamustine	55	93^a	74^a	28
BV-nivolumab	90	85^a	67^a	29
Nivolumab (nivo-ICE)	42 (34 nivolumab alone)	Nivo 81%^a NICE 100%^a	Nivo 71%^aNICE 89%^a	30
Pembrolizumab-GND	38	100%^a	95%^a	16

Regimen	Number of patients	ORR (%)	CR (%)	Reference
Sequential BV-chemo	37	68^a	35^a	24
BV- ESHAP	66	91^a	70^a	25
BV-ICE	16	94^a	69^a	26
BV-DHAP	12	100^a	100^a	27
BV-bendamustine	55	93^a	74^a	28
BV-nivolumab	90	85^a	67^a	29
Nivolumab (nivo-ICE)	42 (34 nivolumab alone)	Nivo 81%^a NICE 100%^a	Nivo 71%^aNICE 89%^a	30
Pembrolizumab-GND	38	100%^a	95%^a	16

PET negative.

DHAP, dexamethasone, cisplatin, cytarabine; ESHAP, etoposide, solumedrol, high-dose cytarabine, and cisplatin; GND, gemcitabine, navelbine, doxorubicin; NICE, nivolumab-ICE.

[ViewLarge]

This Feature Is Available To Subscribers Only